CGTLive’s Weekly Rewind – August 5, 2022

Article

Review top news and interview highlights from the week ending August 5, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Allogeneic Cell Therapy Trial to Initiate in Ovarian Cancer

Avenge Bio previously presented positive preclinical data at the ASGCT 2022 meeting.

2. Craig M. McDonald, MD, on Safety and Efficacy of DMD Cell Therapy

The principal investigator of the HOPE-2 trial discussed safety and efficacy of Capricor’s CAP-1002.

3. REGENXBIO's MPSII Gene Therapy Charts Course to Approval

The FDA will consider RGX-121's BLA in an accelerated approval pathway.

4. IND Cleared for Dual-Targeted CAR T Therapy for B-Cell Malignancies

UCART2022 is an allogeneic therapy that targets both CD20 and CD22.

5. IND Halted for T-Cell Malignancy Multiplex-Edited Cell Therapy

Beam Therapeutics submitted an IND for BEAM-201 in June 2022.

Recent Videos
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.